- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Merck wins FDA OK for vaccine rival to Pfizer's pneumococcal shot | ||
| Di | Intra-Cellular depression drug succeeds in second late-stage study | ||
| Di | Sanofi taps Belharra for immune drug research; AstraZeneca's new cancer drug falls short | ||
| Di | Roche partners with RNA editing biotech Ascidian | ||
| Di | Lingering cholesterol can keep heart risk high. Marea Therapeutics has $190M to target it. | ||
| Mo | Takeda drug for rare types of epilepsy misses goal in late-stage trial | ||
| Mo | Syncona melds two gene therapy biotechs for better shot at new nervous system treatments | ||
| Mo | New data showcase promise, growing pains of CAR-T in autoimmune disease | ||
| Mo | Abortion pill ruling offers measure of relief for FDA, biotech | ||
| Mo | Early patient engagement can improve medication adherence. Here's how. | ||
| Mo | The critical role of comprehensive RNA sequencing in liquid biopsy for biomarker discovery and clinical trials | ||
| Fr | AbbVie joins in latest gastrointestinal drug chase | ||
| Fr | Radiopharma drugmaker Telix pulls US IPO plans | ||
| Fr | Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing | ||
| Do | Supreme Court preserves access to abortion pill in unanimous ruling | ||
| Do | Moderna says next-gen COVID shot effective in study | ||
| Do | Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision | ||
| Do | Versant debuts biotech working on 'anger management for the immune system' | ||
| Do | Pfizer gene therapy for Duchenne fails to meet goals of key trial | ||
| 12.06. | Flagship taps startup to hunt for obesity drugs that might interest Pfizer | ||
| 12.06. | Regenxbio CEO to step down after 15 years | ||
| 12.06. | Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss | ||
| 12.06. | Ultragenyx, Mereo drug reduces fractures in bone disorder study | ||
| 12.06. | Foresite, a biotech venture firm, reloads with $900M fund | ||
| 11.06. | Donanemab approval would fuel growth of amyloid-blocking Alzheimer's drugs, analysts say |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
